Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International filings provide 3 years of Work In Process readings, the most recent being $18.3 million for Q4 2023.

  • On a quarterly basis, Work In Process rose 189.26% to $18.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $18.3 million, a 189.26% increase, with the full-year FY2023 number at $18.3 million, up 189.26% from a year prior.
  • Work In Process hit $18.3 million in Q4 2023 for Kiniksa Pharmaceuticals International, up from $13.4 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $18.3 million in Q4 2023 to a low of $148000.0 in Q1 2022.
  • Median Work In Process over the past 3 years was $6.5 million (2022), compared with a mean of $8.3 million.
  • The widest YoY moves for Work In Process: up 9033.11% in 2023, down 189.26% in 2023.
  • Kiniksa Pharmaceuticals International's Work In Process stood at $4.2 million in 2021, then surged by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
  • The last three reported values for Work In Process were $18.3 million (Q4 2023), $13.4 million (Q3 2023), and $6.6 million (Q2 2023) per Business Quant data.